Much more monitoring of lower risk prostate cancer in US since 2010

According to a brief research letter in the Journal of the American Medical Association this week, there was a major increase in the application of active surveillance (AS) and watchful waiting (WW) in first-line management of prostate cancer between 2010 and 2015. … READ MORE …

Diet, diagnosis, AS, and the management of lower-risk forms of prostate cancer

Over the years there has been a great deal of speculation (and a very small amount of data) suggesting that men who get diagnosed with relatively low-risk forms of prostate cancer may be able to delay progression of their disease by eating the right diet. … READ MORE …

Howard Wolinsky dodges another MRI and another biopsy

Under the heading “Rats, my PSA went up. Do I need another bleeping biopsy?” Howard Wolinsky provides us with the latest “lowdown” on his 8-year-long prostate cancer journey on active surveillance. … READ MORE …

Prognosis of patient progression and outcomes on active surveillance

The prostate cancer research team led by Dr. Peter Pinto at the National Cancer Institute has just published some interesting new information on risk for disease progression in men on active surveillance. … READ MORE …

Picking the right men for initial management on AS

At the recently completed Canadian Uro-oncology Summit in Toronto, Dr. Laurence Klotz gave a very thorough update on active surveillance (AS) and its application in the management of lower-risk forms of localized prostate cancer. … READ MORE …

First-line treatment for prostate cancer and use of antidepressants

According to a recently reported study in the journal European Urology, men who received first-line surgery or radiation therapy for non-metastatic prostate cancer were significantly more likely to have taken an antidepressant 5 years later than comparable men who didn’t get such treatment. … READ MORE …

Is anyone with intermediate-risk prostate cancer a “good” candidate for AS?

There is no longer any doubt that men initially diagnosed with low- and very low-risk forms of prostate cancer are, in most cases, either excellent or good candidates for first-line management on active surveillance (AS). … READ MORE …